Everence Capital Management Inc. boosted its holdings in shares of Biogen Inc (NASDAQ:BIIB) by 13.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,668 shares of the biotechnology company’s stock after buying an additional 566 shares during the quarter. Everence Capital Management Inc.’s holdings in Biogen were worth $1,487,000 at the end of the most recent quarter.
Several other large investors have also modified their holdings of the company. Linscomb & Williams Inc. raised its stake in shares of Biogen by 2.5% in the second quarter. Linscomb & Williams Inc. now owns 1,204 shares of the biotechnology company’s stock valued at $327,000 after acquiring an additional 29 shares during the last quarter. Advisory Services Network LLC raised its stake in shares of Biogen by 2.0% in the second quarter. Advisory Services Network LLC now owns 2,961 shares of the biotechnology company’s stock valued at $803,000 after acquiring an additional 58 shares during the last quarter. Roberts Glore & Co. Inc. IL raised its stake in shares of Biogen by 3.0% in the second quarter. Roberts Glore & Co. Inc. IL now owns 2,438 shares of the biotechnology company’s stock valued at $662,000 after acquiring an additional 70 shares during the last quarter. Girard Partners LTD. raised its stake in shares of Biogen by 16.6% in the third quarter. Girard Partners LTD. now owns 1,125 shares of the biotechnology company’s stock valued at $352,000 after acquiring an additional 160 shares during the last quarter. Finally, IFC Holdings Incorporated FL raised its stake in shares of Biogen by 4.1% in the fourth quarter. IFC Holdings Incorporated FL now owns 4,050 shares of the biotechnology company’s stock valued at $1,293,000 after acquiring an additional 160 shares during the last quarter. 88.11% of the stock is currently owned by institutional investors.
In other news, Director Robert W. Pangia sold 5,832 shares of the company’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $329.65, for a total transaction of $1,922,518.80. Following the completion of the sale, the director now owns 23,539 shares of the company’s stock, valued at approximately $7,759,631.35. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Alexander J. Denner purchased 30,000 shares of the business’s stock in a transaction dated Wednesday, November 29th. The shares were purchased at an average cost of $317.36 per share, with a total value of $9,520,800.00. Following the acquisition, the director now owns 10,029 shares in the company, valued at approximately $3,182,803.44. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 31,560 shares of company stock worth $10,020,858. Company insiders own 0.25% of the company’s stock.
Shares of Biogen Inc (BIIB) traded up $4.99 on Friday, reaching $316.78. 2,009,303 shares of the company were exchanged, compared to its average volume of 1,318,431. Biogen Inc has a twelve month low of $244.28 and a twelve month high of $370.57. The firm has a market cap of $67,018.93, a price-to-earnings ratio of 26.58, a P/E/G ratio of 1.65 and a beta of 0.75. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.07 and a current ratio of 2.34.
Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Thursday, January 25th. The biotechnology company reported $5.26 EPS for the quarter, missing the Zacks’ consensus estimate of $5.44 by ($0.18). Biogen had a net margin of 20.69% and a return on equity of 38.32%. The company had revenue of $3.31 billion during the quarter, compared to analyst estimates of $3.08 billion. During the same quarter last year, the company posted $5.04 EPS. The firm’s quarterly revenue was up 15.1% on a year-over-year basis. analysts anticipate that Biogen Inc will post 24.88 earnings per share for the current year.
A number of brokerages recently weighed in on BIIB. Canaccord Genuity reaffirmed a “hold” rating and set a $350.00 target price on shares of Biogen in a report on Wednesday. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Biogen in a report on Thursday. Oppenheimer boosted their price target on shares of Biogen from $380.00 to $400.00 and gave the company a “buy” rating in a report on Friday, January 26th. Mizuho reissued a “buy” rating and issued a $433.00 price target (up previously from $400.00) on shares of Biogen in a report on Sunday, February 4th. Finally, HC Wainwright reissued a “buy” rating and issued a $363.00 price target (up previously from $340.00) on shares of Biogen in a report on Friday, January 26th. Eight analysts have rated the stock with a hold rating and twenty-four have issued a buy rating to the company’s stock. Biogen presently has a consensus rating of “Buy” and a consensus price target of $368.99.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://ledgergazette.com/2018/02/11/biogen-inc-biib-stake-raised-by-everence-capital-management-inc.html.
Biogen Company Profile
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.